Skip to content

Endoscopic Surgery versus Conventional Craniotomy for the Treatment of Spontaneous Intracerebral Hemorrhage

Treatment Outcome Between Endoscopic Surgery and Conventional Craniotomy for Spontaneous Supratentorial Intracerebral Hemorrhage; a Randomized Controlled Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20200116002
Enrollment
Unknown
Registered
2020-01-16
Start date
2019-03-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spontaneous supratentorial intracerebral hemorrhage intracerebral hemorrhage endoscopic surgery outcome

Interventions

Endoscopic clot removal for treatment of intracerebral hemorrhage ,Conventional treament consists of medical treament and surgery if indicated (uncontrolled increased intracranial pressure&#44
clot expansion)
Active Comparator Procedure/Surgery,Active Comparator Procedure/Surgery
Endoscopic surgery,Conventional treament

Sponsors

none
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. newly diagnosed spontaneous intracerebral hemorrhage in supratentorial area 2. hematoma volume > 30 ml 3. Glasgow coma score 5-14 or NIHSS > 6 4. able to start treatment within 24 hours after the onset 5. SBP < 200 mmHg or MAP < 130 mHG more than 6 hours before treatment 6. Modified Rankin Scale 0-1 before the onset

Exclusion criteria

Exclusion criteria: 1. intracerenral hemorrhage associated with ruptured cerebral aneurysms, vascular malformations, Moyamoya disease, venous sinus thrombosis, tumor, trauma, hemorrhagic transforamtion of cerebral infarction or recurrent hemorrhage within 1 year 2. Bilateral fixed dilated pupils or extensor motor posturing 3. Presence of intraventricular hemorrhage >50% in lateral ventricle or obtructive hydrocephalus 4. infratentorial hemorrhage 5. coagulopathy 6. active bleeding in gastrointestinal, retroperitoneal, or respiratory tract 7. Platelet count < 100,000 or internaltional normalized ratio > 1.3 8. End stage renal or liver disease or other disease contraindicated for surgery 9. pregnancy 10. Unidentified subjects or lack of care-givers

Design outcomes

Primary

MeasureTime frame
Neurologic disability Posttreatment 6 month Modified Rankin Scale

Secondary

MeasureTime frame
Neurologic disability Posttreatment 1 and 3 month Modified Rankin Scale,Mortality Posttreatment Mortality rate,Hematoma removal volume Posttreatment Clot reduction volume,Complications Posttreatment Complication event rate,Rebleeding Posttreatment rebleeding rate,Hospital stay from admission to dischage length of hospital stay (day)

Countries

Thailand

Contacts

Public ContactRaywat Noiphithak

Department of Surgery, Faculty of Medicine, Thammasat University

raywat_n@tu.ac.th6629269523

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026